NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

被引：0
作者：
Munechika Enjoji
Kazuyuki Machida
Motoyuki Kohjima
Masaki Kato
Kazuhiro Kotoh
Kazuhisa Matsunaga
Manabu Nakashima
Makoto Nakamuta
机构：
[1] Fukuoka University,Faculty of Pharmaceutical Sciences
[2] National Hospital Organization,Clinical Research Center, Kyushu Medical Center
[3] National Hospital Organization,Department of Gastroenterology, Kyushu Medical Center
[4] Kyushu University,Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences
来源：
Lipids in Health and Disease | / 9卷
关键词：
Ezetimibe; Nonalcoholic Fatty Liver Disease; NAFLD Patient; Ursodiol; Ezetimibe Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease
    Iwaki, Michihiro
    Kessoku, Takaomi
    Tanaka, Kosuke
    Ozaki, Anna
    Kasai, Yuki
    Yamamoto, Atsushi
    Takahashi, Kota
    Kobayashi, Takashi
    Nogami, Asako
    Honda, Yasushi
    Ogawa, Yuji
    Imajo, Kento
    Oyamada, Shunsuke
    Kobayashi, Noritoshi
    Aishima, Shinichi
    Saito, Satoru
    Nakajima, Atsushi
    Yoneda, Masato
    JGH OPEN, 2022, 6 (10): : 696 - 703
  • [22] The NPC1L1 Polymorphism 1679C>G Is Associated with Gallstone Disease in Chinese Patients
    Wu, Jian
    Cui, Wei
    Cai, Qu
    Fei, Jian
    Zhang, Sheng-Dao
    Han, Tian-Quan
    Hu, Hai
    Jiang, Zhao-Yan
    PLOS ONE, 2016, 11 (01):
  • [23] Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: The significance of dietary cholesterol
    Yasutake, Kenichiro
    Nakamuta, Makoto
    Shima, Yuki
    Ohyama, Akiko
    Masuda, Kaori
    Haruta, Noriko
    Fujino, Tatsuya
    Aoyagi, Yoko
    Fukuizumi, Kunitaka
    Yoshimoto, Tsuyoshi
    Takemoto, Ryosuke
    Miyahara, Toshihiko
    Harada, Naohiko
    Hayata, Fukuko
    Nakashima, Manabu
    Enjoji, Munechika
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (04) : 471 - 477
  • [24] SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease
    Colak, Yasar
    Ozturk, Oguzhan
    Senates, Ebubekir
    Tuncer, Ilyas
    Yorulmaz, Elif
    Adali, Gupse
    Doganay, Levent
    Enc, Feruze Yilmaz
    MEDICAL SCIENCE MONITOR, 2011, 17 (05): : HY5 - HY9
  • [25] Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population
    Shou-Wu Lee
    Teng-Yu Lee
    Sheng-Shun Yang
    Chun-Fang Tung
    Hong-Zen Yeh
    Chi-Sen Chang
    Hepatobiliary&PancreaticDiseasesInternational, 2018, 17 (01) : 45 - 48
  • [26] Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population
    Lee, Shou-Wu
    Lee, Teng-Yu
    Yang, Sheng-Shun
    Tung, Chun-Fang
    Yeh, Hong-Zen
    Chang, Chi-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2018, 17 (01) : 45 - 48
  • [27] Association between Serum Ferritin Level and Nonalcoholic Fatty Liver Disease in a Non-Obese Chinese Population: a Cross-Sectional Study
    Yao, Jinmei
    Dai, Yuying
    Zhang, Juanwen
    Zhang, Xuyao
    Zheng, Ruoheng
    CLINICAL LABORATORY, 2019, 65 (06) : 1075 - 1080
  • [28] Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study
    Cong, Fangyuan
    Zhu, Luying
    Deng, Lihua
    Xue, Qian
    Wang, Jingtong
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [29] Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study
    Fangyuan Cong
    Luying Zhu
    Lihua Deng
    Qian Xue
    Jingtong Wang
    BMC Gastroenterology, 23
  • [30] Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease
    Qiu, Longxin
    Guo, Chang
    CURRENT DRUG TARGETS, 2020, 21 (06) : 599 - 609
12345